Evaluation of CA125 in relation to pain symptoms among adolescents and young adult women with and without surgically-confirmed endometriosis

Naoko Sasamoto1,2*, Mary DePari1,2, Allison F. Vitonis1,2, Marc R. Laufer1,2,3, Stacey A. Missmer1,4,5,6, Amy L. Shafrir1,6, Kathryn L. Terry1,2,4☯

1 Boston Center for Endometriosis, Boston Children’s Hospital and Brigham and Women’s Hospital, Boston, Massachusetts, United States of America, 2 Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, United States of America, 3 Division of Gynecology, Department of Surgery, Boston Children’s Hospital and Harvard Medical School, Boston, Massachusetts, United States of America, 4 Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America, 5 Department of Obstetrics, Gynecology, and Reproductive Biology, College of Human Medicine, Michigan State University, Grand Rapids, Michigan, United States of America, 6 Division of Adolescent and Young Adult Medicine, Department of Medicine, Boston Children’s Hospital and Harvard Medical School, Boston, Massachusetts, United States of America

☯ These authors contributed equally to this work.

* nsasamotobwh.harvard.edu

Abstract

Endometriosis is a painful gynecologic disease affecting one in ten reproductive aged women worldwide. Few studies have correlated this symptomatology with biomarker levels among women with and without endometriosis, and no studies correlating pain with biomarker levels have been performed in young patient populations. The purpose of this study was to examine whether CA125 correlates with different types and severity of pain among adolescents and young women with and without endometriosis and assess its performance as an endometriosis biomarker among those presenting with dysmenorrhea in this young population. Reproductive-aged women with laparoscopically-confirmed endometriosis (n = 282) and controls (n = 293) who participated in The Women’s Health Study: From Adolescence to Adulthood (A2A), a cohort of adolescents and young women enrolled from 2012–2018, were included in this cross-sectional analysis. Plasma CA125 values were measured using WERF EPHect compliant blood samples collected at enrollment. Average CA125 were calculated by self-reported pain type (i.e. dysmenorrhea, non-cyclic/general pelvic pain, dyspareunia), severity, and frequency in endometriosis cases and controls. Median age at blood draw was 24 years in controls and 17 years in cases, with 68% and 89% non-Hispanic white, respectively. Most endometriosis cases (95%) were rASRM stage I/II. Average CA125 values were 12.5 U/mL in controls and 12.1 U/mL in cases adjusted for age. CA125 did not differ by pain type, its severity, or frequency in endometriosis cases and controls. Among participants who reported dysmenorrhea, CA125 did not discriminate endometriosis cases from controls using cutoff of 35 U/mL (AUC = 0.51, 95%CI = 0.50–0.53). Among adolescents and young adult women, CA125 did not correlate with pain type. CA125
the Boston Center for Endometriosis leadership committee (womenshealthstudy@bwh.harvard.edu). Data sharing will require a fully executed Data Usage Agreement.

Funding: Financial support for establishment of and data collection within the A2A cohort was provided by the J. Willard and Alice S. Marriott Foundation and support for assay costs was provided by the Marriott Daughter’s Foundation. N. S. was supported by NCI grant R01 CA193965, W81XWH-19-1-0318, and 2017 BCE/Marriott Family Foundation Trainee Award. S.A.M was supported by NICHD R01 HD094842 and NICHD R21 HD096358. A.L.S. was supported by the Marriott Daughter’s Foundation, NICHD R01 HD094842, and NICHD R21 HD096358. K.L.T. was supported by NCI R01 CA193965, NICHD R01 HD094842, and W81XWH-19-1-0318. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

Introduction

Endometriosis is a painful gynecologic disease affecting one in ten reproductive aged women worldwide [1]. Although over 50% of adults with endometriosis report onset of severe pelvic pain during adolescence, there is an average seven-year delay in diagnosis due to the current gold standard of surgical visualization for definitive diagnosis [2–4]. Presently, no reliable biomarkers exist for non-invasive diagnosis of endometriosis [5, 6]. Though many attempts have been made to identify and validate specific biomarkers, studies have been conducted mostly in adult populations limited by poor methodological quality including small sample sizes, lack of consideration of disease heterogeneity, and inappropriate control groups [6, 7].

Cancer Antigen125 (CA125) is a high molecular-weight glycoprotein normally expressed on tissues derived from the coelomic and mullerian epithelia including the uterus endometrium [8]. CA125 has been reported to be elevated in endometriosis patients and is the most commonly described, extensively studied endometriosis biomarker to date [6, 9–13]. A recent report suggested that CA125 may be predictive of endometriosis in symptomatic women with gynecological pain and/or subfertility [10]. However, this study was based on only 30 endometriosis cases and 28 surgical controls with heterogeneous endometriosis and control subtypes.

Patients with endometriosis have been shown to experience different levels of dysmenorrhea, non-cyclic/general pelvic pain, and dyspareunia, which are the most frequently reported pain outcomes among these women [9]. However, few studies have correlated this symptomatology with biomarker levels, and no studies correlating pain with biomarker levels have been performed in young patient populations. Endometriosis diagnosed in adolescence often presents with pain symptoms and superficial peritoneal lesions, which is often different from endometriosis diagnosed in adults [14]. Thus, it is important to understand biomarker performance in this population when aiming for earlier diagnosis of endometriosis.

The objective of this study was to examine whether CA125 correlates with different types and severity of pain among adolescents and young women with and without endometriosis using data collected at enrollment from the longitudinal cohort of the Women’s Health Study: From Adolescence to Adulthood (A2A).

Material and methods

Study population

The Women’s Health Study: From Adolescence to Adulthood (A2A) is a study of adolescents and women oversampled for those surgically diagnosed with endometriosis, enrolling participants from 2012 to 2018 [14]. Briefly, endometriosis cases were enrolled from Boston Children’s Hospital (BCH) and Brigham and Women’s Hospital (BWH) and were eligible if they were 1) female; 2) aged 7–55 years; and 3) had a surgical diagnosis of endometriosis. Controls at enrollment were selected through a combination of approaches that sampled the underlying population that gave rise to the cases [15]. Specifically, controls were women without a surgical diagnosis of endometriosis and were recruited from clinics at BCH and BWH and from the
local Boston community through local advertisement, online postings, and/or word of mouth. At the time of enrollment, participants were emailed a link to a REDCap survey containing extensive questions assessing lifestyle and reproductive factors as well as level of pain, treatment regimen, and medication use. Participants who did not respond to the email link after three follow-up attempts were mailed a paper copy of the questionnaire. Annual questionnaires were collected via the same methods. All questionnaires collected after January 2014 were World Endometriosis Research Foundation Endometriosis Phenome and Biobanking Harmonization Project (WERF EPHeCT) compliant [16], which are available online (http://endometriosisfoundation.org/ephect). Clinical information for A2A participants undergoing surgery at BCH or BWH were collected using the WERF EPHeCT surgical form, including surgically visualized appearance of peritoneal lesions, endometrioma, and deep infiltrating disease and endometriosis revised American Society for Reproductive Medicine (rASRM) stage [17]. This study was approved by the Institutional Review Board of the BWH (Partners Human Research Committee; 2015P001101). All participants provided written consent for study participation, with parental consent plus participant assent for girls < 18 years.

Pain assessment

Detailed information on symptoms of pain were obtained from the questionnaire completed by all A2A participants at enrollment of the study including whether the participant ever experienced pain with periods (dysmenorrhea), non-cyclic/general pelvic pain (pain not associated with menses), and dyspareunia in their lifetime [16]. Severity of dysmenorrhea, general pelvic pain, and dyspareunia was assessed using the visual analogue scale which is an 11-point numeric pain rating scale with 0 = no pain and 10 = worst imaginable pain [18]. Additionally, information on frequency of dysmenorrhea, general pelvic pain, and dyspareunia was collected.

Blood collection

Blood samples were collected at enrollment in compliance with the standardized tools of WERF EPHeCT [16, 17, 19, 20]. At the time of sample collection, participants completed a biospecimen questionnaire on which they reported date of last menstrual period, timing of last foods/beverages consumed, and recent medication and hormone use. Blood samples were collected, processed into plasma, serum and buffy coats, and stored at \(-80\)\(^\circ\)C per WERF EPHeCT fluids standard operating protocols [20].

CA125 measurement

CA125 was measured in 100\(\mu\)L of plasma using a Food and Drug Administration (FDA)-approved clinical chemiluminescent immunoassay (CA125 II) at the Clinical and Epidemiologic Laboratory at Boston Children’s Hospital. The assay reproducibility for CA125 on the E170 automated instrument was high with coefficient of variation in blinded duplicate samples of 1.15% [21].

Covariates

Information on age, race, body mass index (BMI; kg/m\(^2\)), smoking status, age at menarche, menstrual cycle phase at time of blood draw, hormonal medication and analgesic use within 30 days from blood draw were abstracted from the questionnaire assessed at enrollment and/or biospecimen questionnaire data. For women aged \(\geq\) 20 years, BMI was categorized according to the World Health Organization Criteria: underweight (BMI < 18.5 kg/m\(^2\)), normal
weight (BMI 18.5–24.9 kg/m\(^2\)), overweight (BMI 25–29.9 kg/m\(^2\)), or obese (BMI ≥ 30 kg/m\(^2\)). For those <20 years, the age- and gender-specific BMI Z-score was calculated, and participants were categorized as underweight (Z-score ≤ −2), normal weight (Z-score > −2 to < 1), overweight (Z-score 1–2), or obese (Z-score > 2). For endometriosis cases, information on rASRM stage and endometriosis subtype at surgery closest to blood draw was abstracted from the WERF-EPHect surgical form and self-reported age at first endometriosis symptoms was abstracted from the questionnaire obtained at enrollment of the study.

**Statistical analysis**

Among the 656 participants (347 cases and 306 controls) who had a CA125 measurement for their blood samples collected at enrollment, we excluded participants who did not complete the questionnaire at enrollment (n = 13), completed the questionnaire at enrollment more than 60 days before/after their blood draw at enrollment (n = 59), were enrolled as a control at enrollment, but were diagnosed with endometriosis within 2 years after enrollment (n = 1), and were premenarchal at enrollment (n = 5) for a final analytic sample size of 282 surgically confirmed endometriosis cases and 293 controls.

CA125 values were log-transformed to improve normality. We calculated the age-adjusted geometric means and 95% confidence intervals (CIs) of CA125 for all covariates and pain variables described above. Participants were excluded from analyses where they were missing the main exposure. Trend tests were calculated by modeling the exposure variable categories as ordinal adjusted for continuous age. Logistic regression analysis was used to calculate the Area Under the Curve (AUC) and 95% CIs in discriminating endometriosis cases from controls among participants who reported dysmenorrhea by pain levels using thresholds of 30 U/mL and 35 U/mL. All statistical analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC).

**Results**

In total, 575 participants, including 282 laparoscopically-confirmed endometriosis cases and 293 controls, were included in the analyses (Table 1). Median age at blood draw was 24 years in controls and 17 years in cases, with 68% and 89% non-Hispanic white, respectively. Most (81%) of the cases were using hormonal medication at blood draw compared to only 46% of the controls. The majority of cases (95%) were rASRM stage I or II. Overall, the average CA125 was 14.4 U/mL ranging from 3.6 to 117.8 U/mL.

The average CA125 values were 12.5 (95%CI = 11.8–13.3) U/mL in controls and 12.1 (95% CI = 11.4–12.8) U/mL in cases (p = 0.96), and the association between demographic characteristics and CA125 values were similar in general regardless of disease status (Table 1). Compared to those over age 30, younger age at blood draw was suggestively associated with lower CA125 values. Current smokers had lower CA125 values compared to former or never smokers, although there were only nine current smokers. Participants whose age at menarche was greater than 14 had higher CA125 values on average compared to those whose menarche started at a younger age. CA125 values were higher when blood was drawn during the follicular phase compared to other menstrual cycle phases. Regardless of whether the participants were diagnosed of endometriosis, those who were on hormonal medication at blood draw had lower CA125 values compared to those who were not. Analgesic use at time of blood draw was not associated with CA125 values. Among endometriosis cases, those diagnosed with advanced stage had a higher CA125 compared to those diagnosed with early stage disease. When we examined levels by endometriosis subtypes, those with endometrioma had the highest average CA125 values (51.7, 95%CI = 35.7–74.9 U/mL), although the sample size was limited to five
Table 1. Association between demographic/reproductive factors and circulating CA125 among surgically confirmed endometriosis cases and controls.

| Characteristics                        | Endometriosis (n = 282) | No Endometriosis (n = 293) |
|----------------------------------------|--------------------------|-----------------------------|
|                                        | N (%) | CA125 (U/mL) | N (%) | CA125 (U/mL) |
| Overall                                | 282   | 12.1 (11.4, 12.8) | 293   | 12.5 (11.8, 13.3) |
| Age at blood draw                      |       |               |       |               |
| <18 years old                          | 148 (52.5) | 11.9 (11.1, 12.8) | 10 (3.4) | 12.5 (9.1, 17.4) |
| 18 to < 22 years old                   | 65 (23.1)  | 12.7 (11.3, 14.2) | 58 (19.8) | 11.9 (10.4, 13.6) |
| 22 to < 26 years old                   | 25 (8.9)   | 9.8 (8.2, 11.8)  | 122 (41.6) | 12.0 (10.9, 13.1) |
| 26 to < 30 years old                   | 19 (6.7)   | 12.7 (10.3, 15.6) | 51 (17.4) | 13.7 (11.8, 15.8) |
| 30+ years old                          | 25 (8.9)   | 13.6 (11.4, 16.3) | 52 (17.8) | 13.5 (11.7, 15.6) |
| Race (RACE2)                           |       |               |       |               |
| White                                  | 251 (89.0) | 12.4 (11.7, 13.1) | 198 (68.3) | 12.4 (11.5, 13.3) |
| Non-white                              | 31 (11.0)  | 10.0 (8.5, 11.7)  | 92 (31.7) | 12.9 (11.5, 14.3) |
| Body Mass Index (kg/m²)                |       |               |       |               |
| Underweight                            | 4 (1.4)    | 11.6 (7.4, 18.3)  | 10 (3.4) | 9.4 (6.8, 13.1)  |
| Normal weight                          | 167 (59.6) | 12.5 (11.7, 13.5) | 197 (67.5) | 12.5 (11.6, 13.5) |
| Overweight                             | 60 (21.4)   | 11.6 (10.3, 13.1) | 52 (17.8) | 12.9 (11.2, 14.9) |
| Obese                                  | 49 (17.5)   | 11.5 (10.1, 13.0) | 33 (11.3) | 12.8 (10.7, 15.3) |
| Smoking status                         |       |               |       |               |
| Never                                  | 254 (93.7) | 12.1 (11.4, 12.8) | 268 (91.8) | 12.6 (11.9, 13.4) |
| Former                                 | 14 (5.2)    | 12.0 (9.3, 15.5)  | 18 (6.2) | 11.3 (8.7, 14.5)  |
| Current                                | 3 (1.1)     | 9.5 (5.6, 16.2)   | 6 (2.1) | 9.5 (6.2, 14.4)   |
| Age at menarche                        |       |               |       |               |
| ≤10 years                              | 50 (17.8)   | 11.1 (9.8, 12.7)  | 34 (11.6) | 11.8 (9.9, 14.1)  |
| 11–12 years                            | 147 (52.3)  | 12.5 (11.6, 13.5) | 135 (46.2) | 12.7 (11.6, 13.9) |
| 13–14 years                            | 78 (27.8)   | 11.7 (10.5, 13.0) | 111 (38.0) | 12.3 (11.1, 13.5) |
| >14 years                              | 6 (2.1)     | 15.6 (10.9, 22.9) | 12 (4.1) | 13.9 (10.3, 18.7) |
| Menstrual cycle phase at blood draw    |       |               |       |               |
| Early follicular                       | 6 (17.7)    | 12.1 (7.3, 19.9)  | 24 (15.8) | 17.3 (14.0, 21.3) |
| Late follicular                        | 5 (14.7)    | 17.5 (10.2, 30.0) | 24 (15.8) | 13.3 (10.8, 16.4) |
| Peri-ovulation                         | 2 (5.9)     | 9.0 (3.8, 21.3)   | 10 (6.6) | 12.3 (8.9, 17.0)  |
| Luteal                                 | 8 (23.5)    | 14.5 (9.5, 22.2)  | 41 (27.0) | 13.9 (11.9, 16.4) |
| Long cycles                            | 9 (26.5)    | 15.3 (10.1, 23.1) | 37 (24.3) | 15.1 (12.6, 17.9) |
| Irregular cycles                       | 4 (11.8)    | 12.8 (7.0, 23.3)  | 16 (10.5) | 11.9 (9.2, 15.4)  |
| Hormonal medication use within past 30 days at blood draw |       |               |       |               |
| Not using hormones                     | 39 (19.1)   | 13.7 (11.8, 15.9) | 155 (53.6) | 14.1 (13.0, 15.3) |
| Using hormones                         | 165 (80.9)  | 12.0 (11.1, 12.8) | 134 (46.4) | 10.9 (10.0, 11.9) |
| Analgesic use within past 30 days at blood draw |       |               |       |               |
| Did not use any pain medication        | 37 (19.8)   | 11.4 (9.8, 13.3)  | 155 (60.1) | 12.0 (11.1, 13.0) |
| Used any pain medication               | 150 (80.2)  | 12.1 (11.2, 13.0) | 103 (39.9) | 12.7 (11.5, 14.0) |

Endometriosis-specific

| ASRM Stage                             |       |               |       |               |
| Stage I/II                             | 246 (95.4) | 11.6 (11.0, 12.3) | N/A   | N/A            |
| Stage III/IV                           | 12 (4.7)   | 21.2 (16.4, 27.5) | N/A   | N/A            |

| Endometriosis subtype                  |       |               |       |               |
| Superficial peritoneal lesion only     | 256 (95.9) | 11.7 (11.1, 12.3) | N/A   | N/A            |
| Endometrioma                           | 5 (1.9)    | 51.7 (35.7, 74.9) | N/A   | N/A            |
| Deep infiltrating                      | 5 (1.9)    | 12.2 (8.5, 17.5)  | N/A   | N/A            |
| Endometrioma and Deep infiltrating    | 1 (0.4)    | 37.1 (16.3, 84.7) | N/A   | N/A            |

(Continued)
cases. Endometriosis cases with superficial peritoneal lesions only (n = 256) and those with deep infiltrating endometriosis lesions only (n = 5) had lower CA125 values (11.7, 95% CI = 11.1–12.3 U/mL; 12.2, 95% CI = 8.5–17.5 U/mL respectively). Age at first endometriosis symptom was not associated with CA125.

We examined the association between symptoms of pain type, severity, duration and CA125 values in endometriosis cases and controls (Table 2). Overall, average CA125 values were similar across participants’ self-reported symptoms of ever experiencing dysmenorrhea, general pelvic pain, or dyspareunia. We did not observe a correlation between severity and frequency of these pain types and CA125 values among endometriosis cases or controls (p-trend > 0.05). Since CA125 is strongly influenced by hormonal medication, we examined the association between pain symptoms and CA125 values among controls who were not on hormonal medication at time of blood draw (S1 Table). Controls reporting severe general pelvic pain was associated with higher CA125 (16.3, 95% CI = 11.3–23.6 U/mL) compared to those with mild general pelvic pain (13.4, 95% CI = 9.0–19.9 U/mL) although the trend was not statistically significant (p-value = 0.40). Interestingly, controls who reported never experiencing dyspareunia had higher CA125 (15.3, 95% CI = 13.5–17.4 U/mL) compared to those who ever experienced dyspareunia (13.6, 95% CI = 11.4–16.3 U/mL), with a significant trend by severity within 24 hours after vaginal intercourse (p-trend = 0.04). However, since there were only five control participants who reported severe dyspareunia, this observation may be due to chance.

Among participants with self-reported dysmenorrhea at baseline, we evaluated the performance of CA125 in discriminating endometriosis cases from controls overall and by level of pain severity (Fig 1). Overall, CA125 did not perform well using the clinical cutpoint of 35 U/mL (AUC = 0.51, 95% CI: 0.50–0.53) or 30 U/mL (AUC = 0.51, 95% CI: 0.49–0.53). When examining the performance of CA125 by the level of pain severity (mild, moderate, severe), the performance did not differ in discriminating endometriosis cases from controls using both cutpoints of 35 U/mL and 30 U/mL with AUCs ranging from 0.50 to 0.53.

**Discussion**

In this young population where more than 80% of the participants are age <30, we observed that circulating CA125 levels were not correlated with different pain types and severity in both

### Table 1. (Continued)

| Characteristics                  | Endometriosis (n = 282) | No Endometriosis (n = 293) |
|----------------------------------|-------------------------|---------------------------|
|                                  | N (%) | CA125 (U/mL)b | N (%) | CA125 (U/mL)b |
| Age at first endometriosis symptoms |       |               |       |               |
| ≤ 12 years                       | 87 (34.4) | 12.7 (11.4, 14.0) | N/A   | N/A           |
| 13 years                         | 51 (20.2) | 11.1 (9.7, 12.6) | N/A   | N/A           |
| 14–15 years                      | 74 (29.3) | 12.1 (10.9, 13.5) | N/A   | N/A           |
| ≥ 16 years                       | 41 (16.2) | 12.3 (10.6, 14.3) | N/A   | N/A           |

*Number of missings for characteristic variables: BMI (n = 3), smoking status (n = 12), race (n = 3), age at menarche (n = 2), menstrual cycle phase at blood draw (n = 90), hormonal medication use at time of blood draw (n = 82), Analgesic use at time of blood draw (n = 130), ASRM stage (n = 24), age at first endometriosis symptoms (n = 29).

bGeometric mean (95% CI) adjusted for age (continuous).

*For women aged ≥ 20 years: underweight (BMI < 18.5 kg/m²), normal weight (BMI 18.5–24.9 kg/m²), overweight (BMI 25–29.9 kg/m²), or obese (BMI ≥ 30 kg/m²) according to World Health Organization criteria; For those < 20 years, the age- and gender-specific BMI Z-score was calculated, and participants were categorized as underweight (Z-score ≤ −2), normal weight (Z-score > −2 to < 1), overweight (Z-score 1–2), or obese (Z-score > 2).

dAmong participants not on hormones at the time of blood draw.

https://doi.org/10.1371/journal.pone.0238043.t001
| Table 2. Association between pain symptoms and circulating CA125 among surgically confirmed endometriosis cases and controls$^a$. |
|---------------------------------------------------------------|
| Endometriosis (n = 282) | No Endometriosis (n = 293) |
| **N (%)** | **CA125 (U/mL)$^b$** | **N (%)** | **CA125 (U/mL)$^b$** |
| Dysmenorrhea | | | |
| Ever experienced period pain | | | |
| **N (%)** | **CA125 (U/mL)$^b$** | **N (%)** | **CA125 (U/mL)$^b$** |
| Never | 6 (2.1) | 12.4 (8.5, 18.0) | 52 (17.8) | 12.3 (10.6, 14.1) |
| Ever | 276 (97.9) | 12.1 (11.4, 12.8) | 241 (82.3) | 12.6 (11.8, 13.4) |
| **p-value** | 0.89 | 0.76 | |
| Severity of period pain$^c,d$ | | | |
| Mild | 10 (4.0) | 11.9 (8.9, 15.9) | 62 (21.0) | 12.3 (10.7, 14.0) |
| Moderate | 25 (10.1) | 12.1 (10.1, 14.6) | 97 (44.3) | 11.9 (10.7, 13.3) |
| Severe | 213 (85.9) | 12.2 (11.4, 13.0) | 60 (27.4) | 13.3 (11.6, 15.2) |
| **p-trend** | 0.90 | 0.23 | |
| Frequency of period pain$^c,e$ | | | |
| Never/rarely | 7 (4.4) | 12.3 (8.8, 17.2) | 14 (6.8) | 13.6 (10.4, 17.7) |
| Occasionally | 6 (3.8) | 18.4 (12.8, 26.5) | 72 (35.1) | 10.7 (9.5, 12.0) |
| Often | 6 (3.8) | 15.2 (10.6, 21.7) | 39 (19.0) | 13.7 (11.7, 16.0) |
| Usually | 14 (8.8) | 12.0 (9.5, 15.2) | 34 (16.6) | 11.5 (9.7, 13.6) |
| Always | 127 (79.4) | 11.9 (11.0, 12.8) | 46 (22.4) | 14.0 (12.1, 16.2) |
| **p-trend** | 0.12 | 0.04 | |
| General Pelvic Pain | | | |
| Ever experienced general pelvic pain | | | |
| Never | 91 (32.9) | 12.0 (10.9, 13.3) | 233 (79.8) | 12.4 (11.6, 13.3) |
| Ever | 186 (67.2) | 12.1 (11.3, 12.9) | 59 (20.2) | 12.9 (11.3, 14.8) |
| **p-value** | 0.94 | 0.58 | |
| Severity of general pelvic pain$^d,f$ | | | |
| Mild | 12 (7.6) | 14.5 (11.2, 18.8) | 10 (25.6) | 12.2 (8.8, 17.0) |
| Moderate | 29 (18.4) | 11.0 (9.3, 13.0) | 13 (33.3) | 11.6 (8.7, 15.5) |
| Severe | 117 (74.1) | 12.3 (11.3, 13.3) | 16 (41.0) | 13.3 (10.2, 17.2) |
| **p-trend** | 0.77 | 0.51 | |
| Frequency of general pelvic pain$^e,f$ | | | |
| 2–3 days/month or fewer | 27 (28.4) | 12.3 (10.5, 14.5) | 25 (73.5) | 11.7 (9.5, 14.6) |
| 1–6 days per week | 39 (41.1) | 12.1 (10.6, 13.9) | 9 (26.5) | 14.3 (10.0, 20.5) |
| Every day | 29 (30.5) | 11.9 (10.2, 14.0) | 0 (0.0) | N/A |
| **p-trend** | 0.81 | N/A | |
| Dyspareunia | | | |
| Ever experienced dyspareunia$^g$ | | | |
| Never | 22 (20.6) | 12.7 (10.1, 15.9) | 132 (61.1) | 13.0 (11.9, 14.2) |
| Ever | 85 (79.4) | 12.0 (10.6, 13.4) | 84 (38.9) | 12.2 (10.9, 13.7) |
| **p-value** | 0.67 | 0.39 | |
| Severity of dyspareunia within 24 hours after vaginal intercourse/penetration$^d,e,g,h$ | | | |
| Mild | 26 (44.8) | 13.8 (11.2, 16.9) | 149 (85.6) | 12.5 (11.5, 13.6) |
| Moderate | 15 (25.9) | 12.8 (9.7, 16.8) | 17 (9.8) | 15.1 (11.9, 19.2) |
| Severe | 17 (29.3) | 10.7 (8.4, 13.8) | 8 (4.6) | 9.5 (6.7, 13.5) |
| **p-trend** | 0.15 | 0.12 | |
| Frequency of dyspareunia$^g,i$ | | | |
| Occasionally | 21 (25.0) | 11.8 (9.2, 15.1) | 53 (69.7) | 11.9 (10.4, 13.7) |
| Often | 17 (20.2) | 11.4 (8.7, 14.9) | 10 (13.2) | 11.3 (8.2, 15.6) |
| Usually | 21 (25.0) | 12.9 (10.1, 16.5) | 11 (14.5) | 13.9 (10.1, 19.0) |
| (Continued) | | | |
laparoscopically-confirmed endometriosis cases and controls. We also showed that CA125 did not perform well discriminating endometriosis cases from controls in young women presenting with dysmenorrhea.

To our knowledge, this is the first study reporting the correlation between different types and severity of pain and CA125 levels in young women with and without endometriosis. Emerging evidence suggests pain is a heterogeneous, multifaceted condition [22], and therefore it is plausible that molecular features may differ by different pain presentations. While we did not observe significant association between pain and CA125, one small study (n = 69)

![Table 2. (Continued)](https://doi.org/10.1371/journal.pone.0238043.t002)

| Endometriosis (n = 282) | No Endometriosis (n = 293) |
|-------------------------|-----------------------------|
|                         | N (%) | CA125 (U/mL)\(^b\) | N (%) | CA125 (U/mL)\(^b\) |
| Always                  | 25 (29.8) | 11.6 (9.3, 14.5) | 2 (2.6) | 6.2 (3.0, 12.8) |
| p-trend                 | 0.79 | 0.79 |

\(^a\)Number of missings for pain variables: severity of period pain (n = 12), frequency of period pain (n = 14), ever experienced general pelvic pain (n = 6), severity of general pelvic pain (n = 11), ever dyspareunia (n = 1), severity of dyspareunia (n = 7), frequency of dyspareunia (n = 9).

\(^b\)Geometric mean (95%CI) adjusted for age (continuous).

\(^c\)Among participants who experienced period pain within the last 12 months.

\(^d\)Severity of pain was categorized based on the VAS scale: Mild (1–3), Moderate (4–6), Severe (7–10).

\(^e\)Among participants who answered the WERF EPHeCT version of the questionnaire.

\(^f\)Among participants who experienced general pelvic pain within the last 3 months.

\(^g\)Among participants aged 18 or older and reported ever having vaginal intercourse/penetration.

\(^h\)Among participants who reported having dyspareunia in the last 12 months.

Fig 1. Performance of CA125 in discriminating endometriosis cases from controls among participants presenting with dysmenorrhea in the adolescence to adulthood study. (A) Receiver Operating Curves (ROC) using CA125 cutoff of 35 U/mL and (B) using CA125 cutoff of 30 U/mL among participants presenting with dysmenorrhea (overall = solid line; mild pain = dashed line; moderate pain = dotted line; severe pain = dash-dotted line).

https://doi.org/10.1371/journal.pone.0238043.g001
observed higher CA125 in endometriosis patients with severe dysmenorrhea and dyspareunia compared to patients with no pain, although the association was not statistically significant [23]. This inconsistent observation may be in part due to more than 80% of our endometriosis cases using hormonal medication at blood draw, resulting in lower CA125 and attenuating the CA125 differences by pain types and severity. In addition, this inconsistency may also be due to differences in age groups, clinical presentation, and differences in the definition of “pain severity”, since pain severity could be defined in multiple ways (e.g. severity on average over the life course, severity in the past 12 months) between our study and the prior publication. Furthermore, CA125 values could have been influenced by different therapeutic strategies which are available to treat endometriosis other than hormone therapy, such as differences in surgical procedures, phytotherapy with the use of medicinal plants, and supplementation [24–26]. We did not observe a significant association between recent analgesic use and CA125, however, the associations between common medication use and CA125 is still limited.

In our study, CA125 did not perform well in discriminating endometriosis cases from controls in young women. Although CA125 has consistently been reported to be associated with endometriosis, many prior studies combined patients with diverse clinical phenotypes and categorized endometriosis as one disease [5, 6, 9]. In fact, recent studies support that multiple molecular mechanisms are involved in endometriosis pathogenesis, including the complex genetic nature and epigenetic mechanisms influencing hormonal, immunologic, and inflammatory aberrations in endometriosis patients [27, 28]. The heterogeneous presentation and molecular mechanisms underlying endometriosis suggest different etiological pathways by subtypes and combining these subtypes into a single endometriosis definition in prior studies may have thwarted progress in finding a reproducible endometriosis biomarker, as a clear signal with any given subtype being overwhelmed by the differences between subtypes [17].

While we did not observe improved discriminatory performance in CA125 after accounting for severity of dysmenorrhea, there have been few studies that reported CA125 performed well in discriminating endometriosis cases from those without among women with pain symptoms [10, 23, 29]. This inconsistent observation could be due in part to the differences in endometriosis phenotype and age range of the study participants. Prior studies reported CA125 does not perform as well in detecting minimal to mild endometriosis (rASRM stage I/II) [30–32], which is known to be the predominant clinical phenotype of adolescent endometriosis [14, 33, 34]. Furthermore, the average age of endometriosis cases in one prior study was 34 while the average age in our endometriosis cases was 19.6. Therefore, CA125 values measured in adolescents and young women may need to be interpreted differently with more caution.

To our knowledge, this is the first study that reported demographic characteristics in relation to CA125 values in healthy adolescents and young women. CA125 is known to be influenced by personal characteristics in healthy individuals [12, 35–38], and only two studies have examined correlates of CA125 in premenopausal women, with the youngest age category being women age <30 years [12, 35]. Consistent with prior studies, we observed that current smoking and hormone use at blood draw was associated with lower CA125, and blood draw at follicular phase was associated with higher CA125 in controls. Interestingly, young women in their late teens and early 20s had lower CA125 compared to those age 30 or older, suggesting we may need to consider lower thresholds when interpreting CA125 values among these healthy young women.

The major strength of our study is the large sample of adolescents and young women with laparoscopically-diagnosed endometriosis and use of controls sampled from the underlying population that gave rise to the cases. Our study participants were also well annotated for their pain symptoms and had valid biomarker measurements using the WERF EPHect compliant questionnaires and biospecimens. However, due to the case-control design of the study,
symptoms of pain may have been recalled differently in cases compared to controls, which may have led to over or underestimation of the association. Since most of the participants were on hormonal medication at time of blood draw, we were not able to stratify all our analyses by use of hormonal medication, which is known to influence CA125 values. This may have limited the ability to detect the association between different symptoms of pain and CA125 values. However, given that many young women currently use hormonal medication, we believe our current results are generalizable. Moreover, the clinical utility of CA125 in tailoring treatment in women with pelvic pain is still unclear. Our study consisted primarily of a white population and was based in a specific region of the United States, which may limit the generalizability of our study results.

Conclusion
Our analyses suggest that CA125 values do not correlate with types of pain (i.e. dysmenorrhea, acyclic pain, and dyspareunia), or its severity or frequency among adolescents and young adult women. CA125 did not efficiently discriminate endometriosis cases from controls using the clinical cutpoints of 35 U/mL or 30 U/mL even when accounting for pain symptomatology in this young population. Average blood CA125 values were low in adolescents and young women in both endometriosis cases and controls, suggesting that cautious interpretation may be needed when measuring CA125 in adolescents and young women.

Supporting information
S1 Table. Association between pain symptoms and circulating CA125 among controls not on hormones at time of blood draw.

(DOCX)

Acknowledgments
The authors would like to thank all the participants of the Women’s Health Study: From Adolescence to Adulthood for their valuable contributions and all staffs of the Boston Center for Endometriosis.

Author Contributions
Conceptualization: Naoko Sasamoto, Amy L. Shafrir, Kathryn L. Terry.
Data curation: Mary DePari, Allison F. Vitonis, Amy L. Shafrir.
Formal analysis: Naoko Sasamoto, Mary DePari, Allison F. Vitonis, Amy L. Shafrir.
Funding acquisition: Marc R. Laufer, Stacey A. Missmer.
Methodology: Naoko Sasamoto, Allison F. Vitonis, Stacey A. Missmer, Amy L. Shafrir, Kathryn L. Terry.
Project administration: Allison F. Vitonis, Stacey A. Missmer.
Resources: Allison F. Vitonis.
Software: Allison F. Vitonis.
Supervision: Stacey A. Missmer, Amy L. Shafrir, Kathryn L. Terry.
Visualization: Naoko Sasamoto.
Writing – original draft: Naoko Sasamoto.
References

1. Zondervan KT, Becker CM, Koga K, Missmer SA, Taylor RN, Viganò P. Endometriosis. Nature reviews Disease primers. 2018; 4(1):9. https://doi.org/10.1038/s41572-018-0008-5 PMID: 30026507

2. Hudelist G, Fritzler N, Thomas A, Niehues C, Oppelt P, Haas D, et al. Diagnostic delay for endometriosis in Austria and Germany: causes and possible consequences. Human reproduction. 2012; 27(12):3412–6. https://doi.org/10.1093/humrep/des316 PMID: 22990516

3. Nnoaham KE, Hummelshoj L, Webster P, d’Hooghe T, de Cicco Nardone F, de Cicco Nardone C, et al. Impact of endometriosis on quality of life and work productivity: a multicenter study across ten countries. Fertility and sterility. 2011; 96(2):366–73 e8. https://doi.org/10.1016/j.fertnstert.2011.05.090 PMID: 21718982

4. Youngster M, Laufer MR, Divasta AD. Endometriosis for the primary care physician. Current opinion in pediatrics. 2013; 25(4):454–62. https://doi.org/10.1097/MOP.0b013e3283628092 PMID: 23817302

5. May KE, Conduit-Hulbert SA, Villar J, Kirtley S, Kennedy SH, Becker CM. Peripheral biomarkers of endometriosis: a systematic review. Human reproduction update. 2010; 16(6):651–74. https://doi.org/10.1093/humupd/dmq009 PMID: 20462942

6. Nisenblat V, Bossuyt PM, Shaikh R, Farquhar C, Scheffers CS, et al. Blood biomarkers for the non-invasive diagnosis of endometriosis. The Cochrane database of systematic reviews. 2016(5):CD012179. https://doi.org/10.1002/14651858.CD012179 PMID: 27132058

7. Missmer SA. Why so null? Methodologic necessities to advance endometriosis discovery. Paediatric and perinatal epidemiology. 2019; 33(1):26–7. https://doi.org/10.1111/ppe.12540 PMID: 30698886

8. Haridas D, Ponnusamy MP, Chugh S, Lakshmanan I, Seshacharyulu P, Batra SK. MUC16: molecular analysis and its functional implications in benign and malignant conditions. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2014; 28(10):4183–99.

9. Hirsch M, Duffy J, Davis CJ, Nieves Plana M, Khan KS, International Collaboration to Harmonise O, et al. Diagnostic accuracy of cancer antigen 125 for endometriosis: a systematic review and meta-analysis. BJOG: an international journal of obstetrics and gynaecology. 2016; 123(11):1761–8.

10. Hirsch M, Duffy JMN, Deguara CS, Davis CJ, Khan KS. Diagnostic accuracy of Cancer Antigen 125 (CA125) for endometriosis in symptomatic women: A multi-center study. European journal of obstetrics, gynecology, and reproductive biology. 2017; 210:102–7. https://doi.org/10.1016/j.ejogrb.2016.12.002 PMID: 27987404

11. Moretuzzo RW, DiLauro S, Jenison E, Chen SL, Reindollar RH, McDonough PG. Serum and peritoneal lavage fluid CA-125 levels in endometriosis. Fertility and sterility. 1988; 50(3):430–3. https://doi.org/10.1016/s0015-0282(16)60127-9 PMID: 2457518

12. Sasamoto N, Baibic A, Rosner BA, Fortner RT, Vitonis AF, Yamamoto H, et al. Predicting Circulating CA125 Levels among Healthy Premenopausal Women. Cancer Epidemiol Biomarkers Prev. 2019; 50(3):430–3. https://doi.org/10.1016/s0953-8562(19)30614-2 PMID: 31558697

13. Shen A, Xu S, Ma Y, Guo H, Li C, Yang C, et al. Diagnostic value of serum CA125, CA19-9 and CA15-3 in endometriosis: A meta-analysis. The Journal of international medical research. 2015; 43(5):599–609. https://doi.org/10.1177/0300060515583076 PMID: 26246541

14. DiVasta AD, Vitonis AF, Laufer MR, Missmer SA. Spectrum of symptoms in women diagnosed with endometriosis during adolescence vs adulthood. American journal of obstetrics and gynecology. 2018; 218(3):324 e1–e11. https://doi.org/10.1016/j.ajog.2017.12.007 PMID: 29247637

15. Modern epidemiology Third ed. KJ R, editor. Philadelphia,: Wolters Kluwer Health/Lippincott Williams & Wilkins 2008.

16. Vitonis AF, Vincent K, Rahmioglu N, Fassbender A, Buck Louis GM, Hummelshoj L, et al. World Endometriosis Research Foundation Endometriosis Phenome and Biobanking Harmonization Project: II. Clinical and covariate phenotype data collection in endometriosis research. Fertility and sterility. 2014; 102(5):1223–32. https://doi.org/10.1016/j.fertnstert.2014.07.1244 PMID: 25256930

17. Becker CM, Laufer MR, Stratton P, Hummelshoj L, Missmer SA, Zondervan KT, et al. World Endometriosis Research Foundation Endometriosis Phenome and Biobanking Harmonisation Project: I. Surgical phenotype data collection in endometriosis research. Fertility and sterility. 2014; 102(5):1213–22. https://doi.org/10.1016/j.fertnstert.2014.07.0709 PMID: 25150390

18. Vincent K, Kennedy S, Stratton P. Pain scoring in endometriosis: entry criteria and outcome measures for clinical trials. Report from the Art and Science of Endometriosis meeting. Fertility and sterility. 2010; 93(1):62–7. https://doi.org/10.1016/j.fertnstert.2008.09.056 PMID: 18990378
19. Fassbender A, Rahmioglu N, Vitonis AF, Vigano P, Giudice LC, D’Hooghe TM, et al. World Endometriosis Research Foundation Endometriosis Phenome and Biobanking Harmonization Project: IV. Tissue collection, processing, and storage in endometriosis research. Fertility and sterility. 2014; 102(5):1244–53. https://doi.org/10.1016/j.fertnstert.2014.07.1209 PMID: 25256928

20. Rahmioglu N, Fassbender A, Vitonis AF, Tworoger SS, Hummelshoj L, D’Hooghe TM, et al. World Endometriosis Research Foundation Endometriosis Phenome and Biobanking Harmonization Project: III. Fluid biospecimen collection, processing, and storage in endometriosis research. Fertility and sterility. 2014; 102(5):1233–43. https://doi.org/10.1016/j.fertnstert.2014.07.1208 PMID: 25256929

21. Skates SJ, Mai P, Horick NK, Piedmonte M, Drescher CW, Isaacs C, et al. Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status. Cancer Prev Res (Phila). 2011; 4(9):1401–8.

22. Carey ET, Till SR, As-Sanie S. Pharmacological Management of Chronic Pelvic Pain in Women. Drugs. 2017; 77(3):285–301. https://doi.org/10.1007/s40265-016-0687-8 PMID: 28074359

23. Maiorana A, Cicerone C, Niceta M, Alio L. Evaluation of serum CA 125 levels in patients with pelvic pain related to endometriosis. The International journal of biological markers. 2007; 22(3):200–2. https://doi.org/10.5301/jbm.2008.5555 PMID: 17922463

24. Della Corte L, Noventa M, Ciebiera M, Magliarditi M, Sleiman Z, Karaman E, et al. Phytotherapy in endometriosis: an up-to-date review. J Complement Integr Med. 2019.

25. Giampaolino P, Della Corte L, Foreste V, Bifulco G. Is there a Relationship Between Vitamin D and Endometriosis? An Overview of the Literature. Curr Pharm Des. 2019; 25(22):2421–7. https://doi.org/10.2174/1381612825666190722095401 PMID: 31333100

26. Giampaolino P, Della Corte L, Saccone G, Vitagliano A, Bifulco G, Calagna G, et al. Role of Ovarian Suspension in Preventing Postoperative Ovarian Adhesions in Patients with Stage III-IV Pelvic Endometriosis: A Systematic Review. J Minim Invasive Gynecol. 2019; 26(1):53–62. https://doi.org/10.1016/j.jmig.2018.07.021 PMID: 30092363

27. Lagana AS, Garzon S, Gotte M, Vigano P, Franchi M, Ghezzi F, et al. The Pathogenesis of Endometriosis: Molecular and Cell Biology Insights. Int J Mol Sci. 2019; 20(22).

28. Riemma G, Lagana AS, Schiattarella A, Garzon S, Cobellis L, Autiero R, et al. Ion Channels in The Pathogenesis of Endometriosis: A Cutting-Edge Point of View. Int J Mol Sci. 2020; 21(3).

29. Daher RMF, Rosa ESJC, Poli-Neto OB, Candido-Dos-Reis FJ, Nogueira AA. Diagnosis of endometriosis in women with chronic pelvic pain. Clinical and experimental obstetrics & gynecology. 2016; 43(4):512–5. PMID: 29734538

30. Gajbhiye R, Bendigeri T, Ghuge A, Bhusane K, Begum S, Warty N, et al. Panel of Autoimmune Markers for Noninvasive Diagnosis of Minimal-Mild Endometriosis. Reproductive sciences. 2017; 24(3):413–20. https://doi.org/10.1177/1933719116657190 PMID: 27485360

31. Barbosa CP, Souza AM, Bianco B, Christofolini D, Bach FA, Lima GR. Frequency of endometriotic lesions in peritoneum samples from asymptomatic fertile women and correlation with CA125 values. Sao Paulo medical journal = Revista paulista de medicina. 2009; 127(6):342–5. https://doi.org/10.1590/s1516-31802009000600004 PMID: 20512287

32. Riley CF, Moen MH, Videm V. Inflammatory markers in endometriosis: reduced peritoneal neutrophil response in minimal endometriosis. Acta obstetricia et gynecologica Scandinavica. 2007; 86(7):877–81. https://doi.org/10.1080/00016340701417398 PMID: 17611835

33. Lauf MR, Sanfilippo J, Rose G. Adolescent endometriosis: diagnosis and treatment approaches. Journal of pediatric and adolescent gynecology. 2003; 16(3 Suppl):S3–11.

34. Saridogan E. Adolescent endometriosis. European journal of obstetrics, gynecology, and reproductive biology. 2017; 209:46–9.

35. Fortner RT, Vitonis AF, Schock H, Husing A, Johnson T, Fichorova RN, et al. Correlates of circulating ovarian cancer early detection markers and their contribution to discrimination of early detection models: results from the EPIC cohort. Journal of ovarian research. 2017; 10(1):20. https://doi.org/10.1186/s13048-017-0315-6 PMID: 28320479

36. Johnson CC, Kessel B, Riley TL, Ragard LR, Williams CR, Xu JL, et al. The epidemiology of CA-125 in women without evidence of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial. Gynecologic oncology. 2008; 110(3):383–9. https://doi.org/10.1016/j.ygyno.2008.05.006 PMID: 18566313

37. Pauler DK, Menon U, McIntosh M, Symecko HL, Skates SJ, Jacobs IJ. Factors influencing serum CA125II levels in healthy postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2001; 10(5):489–93. PMID: 11352859
38. Sasamoto N, Babic A, Rosner BA, Fortner RT, Vitionis AF, Yamamoto H, et al. Development and validation of circulating CA125 prediction models in postmenopausal women. Journal of ovarian research. 2019; 12(1):116. https://doi.org/10.1186/s13048-019-0591-4 PMID: 31771659